Drug Profile
Hydrocortisone - Diurnal
Alternative Names: Alkindi; ALKINDI SPRINKLE; Chronocort; DNL-0200; Efmody; EFMODY; Hydrocortisone extended release - Diurnal; Infacort; Modified-release hydrocortisoneLatest Information Update: 19 Jun 2023
Price :
$50
*
At a glance
- Originator Diurnal
- Developer Diurnal; EffRx; Emerge Health; Eton Pharmaceuticals; Medison Pharma
- Class Anti-inflammatories; Antiallergics; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Adrenal insufficiency; Congenital adrenal hyperplasia
Most Recent Events
- 15 Jun 2023 The European Commission approves a MAA for Congenital adrenal hyperplasia in EU
- 15 Jun 2023 The Medicines and Healthcare products Regulatory Agency (MHRA) approves a Marketing Authorization application (MAA) for Congenital adrenal hyperplasia in UK
- 29 May 2023 EffRx has been acquired by Abiogen Pharma